Perceptive Advisors Llc Sells 3,400,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. This represents a 36.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Aldeyra Therapeutics Trading Down 1.5 %

Aldeyra Therapeutics stock opened at $1.92 on Wednesday. Aldeyra Therapeutics, Inc has a one year low of $1.14 and a one year high of $7.20. The business has a fifty day moving average of $5.81 and a two-hundred day moving average of $5.36. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). Research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on ALDX. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, April 4th. BTIG Research decreased their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday.

Hedge Funds Weigh In On Aldeyra Therapeutics

Hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC purchased a new position in shares of Aldeyra Therapeutics in the fourth quarter valued at $52,000. Balyasny Asset Management L.P. acquired a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $56,000. Paloma Partners Management Co bought a new stake in Aldeyra Therapeutics during the third quarter valued at $62,000. Catalyst Funds Management Pty Ltd lifted its holdings in Aldeyra Therapeutics by 2,083.3% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 12,500 shares during the last quarter. Finally, Regal Investment Advisors LLC bought a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.